A detailed history of Fmr LLC transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Fmr LLC holds 7,935,735 shares of GOSS stock, worth $6.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,935,735
Previous 7,930,508 0.07%
Holding current value
$6.51 Million
Previous $7.14 Million 10.07%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.79 - $1.25 $4,129 - $6,533
5,227 Added 0.07%
7,935,735 $7.86 Million
Q2 2024

Aug 13, 2024

SELL
$0.51 - $1.27 $131,905 - $328,471
-258,639 Reduced 3.16%
7,930,508 $7.14 Million
Q1 2024

May 13, 2024

SELL
$0.8 - $1.51 $3.26 Million - $6.15 Million
-4,074,771 Reduced 33.23%
8,189,147 $9.66 Million
Q4 2023

Feb 13, 2024

BUY
$0.48 - $1.08 $5.58 Million - $12.6 Million
11,625,497 Added 1820.98%
12,263,918 $11.2 Million
Q3 2023

Nov 13, 2023

BUY
$0.78 - $1.82 $495,200 - $1.16 Million
634,873 Added 17893.83%
638,421 $529,000
Q2 2023

Aug 11, 2023

BUY
$0.98 - $1.53 $328 - $512
335 Added 10.43%
3,548 $4,000
Q1 2023

May 11, 2023

SELL
$0.96 - $2.92 $51,033 - $155,227
-53,160 Reduced 94.3%
3,213 $4,000
Q4 2022

Feb 13, 2023

SELL
$1.74 - $12.87 $2.14 Million - $15.8 Million
-1,230,333 Reduced 95.62%
56,373 $122,000
Q3 2022

Nov 10, 2022

BUY
$7.21 - $14.88 $2.42 Million - $5 Million
335,700 Added 35.3%
1,286,706 $15.4 Million
Q2 2022

Aug 12, 2022

SELL
$5.97 - $9.97 $1,564 - $2,612
-262 Reduced 0.03%
951,006 $7.96 Million
Q1 2022

May 13, 2022

BUY
$8.44 - $12.49 $479,121 - $709,032
56,768 Added 6.35%
951,268 $8.26 Million
Q3 2021

Nov 15, 2021

BUY
$7.25 - $13.23 $6.49 Million - $11.8 Million
894,500 New
894,500 $11.2 Million

Others Institutions Holding GOSS

About Gossamer Bio, Inc.


  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $77M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track This Portfolio

Track Fmr LLC Portfolio

Follow Fmr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.